Wegovy for Seniors: Evidence, Eligibility, Coverage

Wegovy has no separate rule for adults 65 and older. It is approved for weight loss, heart risk and MASH liver disease. In SELECT: 6.5% for stroke, heart attack, or death from heart disease, vs 8% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection or daily tablet
Approved for: Weight loss, heart risk and MASH liver disease
Best result (SELECT): 6.5% for stroke, heart attack, or death from heart disease
Medicare GLP-1 Bridge: $50 per month

A quick look at Wegovy

How long it stays inside you

The half-life is about 1 week. After 7 d, half is gone, and about 3% remains after five half-lives (35 d).

Weight loss in its main trial

In STEP 1 at 68 weeks, weight loss was 14.9% of body weight, while the placebo group lost 2.4%.

Costs as time goes by

Monthly prices are given in US dollars. These cover the list price and self-pay offers, each one coming from the price page the maker provides.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Wegovy: who qualifies
Who sets the rule	Who qualifies
FDA label	For adults with heart disease plus obesity or overweight, injections or tablets lower the risk of heart attack, stroke, and heart-related death.
FDA label	For adults or children 12 and older with obesity, it helps with weight loss and keeping weight off over the long term when paired with diet and activity.
FDA label	For adults with moderate to advanced scarring and no cirrhosis, it treats MASH liver disease through injection.
FDA label	Tablets are approved for adults to help with weight loss and lower heart risk.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Heart failure, uncontrolled blood pressure, or CKD 3a+, with BMI of 30 or higher
Medicare GLP-1 Bridge	BMI 27 or higher, plus prediabetes, prior heart attack or stroke, or PAD

See medicare.gov 1 2, plus the FDA label (DailyMed).

Trial results for seniors

Wegovy trials with older adults
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SELECT	Wegovy	Adults with no diabetes, who were 45 or older, had heart disease and overweight or obesity	39.8 months (follow-up)	17,604	6.5% for stroke, heart attack, or death from heart disease	8% on placebo

Trial sources: SELECT (PubMed).

What is different for seniors?

Label points on Wegovy for older adults
What changes	What the label says
Hypoglycemia	Low blood sugar is more likely when you combine it with insulin or a sulfonylurea, so those doses may need to be lowered.
Acute Kidney Injury Due to Volume Depletion	Kidney injury can result from vomiting or diarrhea that causes fluid loss. Drink fluids and report heavy fluid loss.
Heart Rate Increase	Can raise resting heart rate. Tell your doctor about a racing or pounding heart while you are at rest.
Taken with insulin or sulfonylureas	Taking it with insulin or a sulfonylurea, such as glipizide or glimepiride, makes low blood sugar more likely. Your doctor may lower the doses.

Taken from the FDA labels: FDA label (DailyMed).

Label warnings: FDA label on DailyMed.

Coverage for seniors

Medicare Part D may cover these medicines if they are prescribed for diabetes or cardiovascular disease.

Part D plans may cover a GLP-1 used for type 2 diabetes, fatty liver disease, or moderate to severe sleep apnea.

Medicare Part D does not cover a GLP-1 when you take it only for weight loss.

People who meet the Medicare GLP-1 Bridge rules can find Wegovy on its list at $50 per month.

Weight-loss GLP-1s usually need prior authorization from Medicaid programs that cover them.

Sources: humana.com, medicare.gov, CMS, KFF.

Alternatives for seniors

GLP-1 medicines and older adults
Medicine	For older adults	How it is taken	Trial result
Wegovy	Approved uses apply	weekly injection or daily tablet	6.5% for stroke, heart attack, or death from heart disease
Ozempic	Approved uses apply	weekly injection	Not listed
Rybelsus	Approved uses apply	daily tablet	12% for heart attack, stroke, or heart disease death
Mounjaro	Approved uses apply	weekly injection	Not listed
Zepbound	Approved uses apply	weekly injection	Not listed
Foundayo	Approved uses apply	daily tablet	Not listed
Trulicity	Approved uses apply	weekly injection	12% for heart attack, stroke, or heart disease death
Saxenda	Approved uses apply	daily injection	Not listed
Victoza	Approved uses apply	daily injection	Not listed
Byetta	Approved uses apply	twice-daily injection	Not listed